: iStockAnalyst.com Symbols Feed

CombiMatrix: Array Of Sunshine In '09?

Thu, 15 Jan 2009 14:08:00 GMT

The accompanying table (click to enlarge) includes statistics for all 40 companies included in the ETF Innovators Emerging Diagnostics Index of stocks with market caps of less than $150M and an average market value of $50M. The index has lost nearly 54% of its value in the past year, compared to declines of about 40% each for the S&P 500 SPDR ETF (SPY) + iShares Russell Micro-Cap ETF (IWC), 29% for the Healthcare Sector SPDR (XLV), and 15% for the SPDR S&P Biotech ETF (XBI).[More...]

A New Emerging Diagnostics Index

Fri, 26 Dec 2008 15:27:00 GMT

The accompanying table (click to enlarge) includes 39 companies in the ETF Innovators (ETFI) Emerging Diagnostics Index of U.S.-listed stocks with market caps of $10-$200M. The index includes diabetes care device makers such as DexCom (DXCM), personalized medicine lab service providers such as Clarient (CLRT), clinical diagnostic test developers such as OraSure (OSUR), diagnostic imaging service providers such as Virtual Radiologic (VRAD), diagnostic equipment makers such as Vision Sciences (VSCI), and genetic[More...]

YM BioSciences Announces Phase 2 Metastatic Colorectal Cancer Results for Nimotuzumab

Tue, 05 Aug 2008 17:02:00 GMT

The table below compares nimotuzumab (nimo) + irinotecan (N-Mab + Iri) data against results obtained from an integrated analysis of four trials of patients treated with Erbitux (cetuximab) + irinotecan (C-Mab + Iri) following irinotecan failure in a similar patient population: YM BioSciences (YMI) announced preliminary results from a Phase 2 study of nimo in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC). The data are based on 58 evaluable patients of the 61 enrolled in the trial. The prospective primary endpoint in the trial is[More...]

Nine Stocks Strike Back

Tue, 05 Aug 2008 15:14:00 GMT

Blah blah here are 9 stocks, only 1 or 2 looks really interesting to me, the rest are just potentially setting upNTRZ is a successful spammer, look at everyone they used…Any company that hires that many spammers is so friggin desperate, they should have an ABC TV series called “Desperate Frauds” very “Sopranos”-like….yes, reserve shares, and pray to god they paid enough money to get their stock price higher cuz right now there’s only 20 cents/share of downside..thids is my #1 potential short, but I really want to only short after $1CSK announced a refinancing, forget shorting this one … (visit site to read more)[More...]

Health Discovery Corporation Announces Additional Issued Patents and Notices of Allowance to Its Intellectual Property Portfolio

Mon, 19 Oct 2009 13:48:00 GMT

New U.S. and Foreign Patents
The United States Patent and Trademark Office (USPTO) issued a patent to HDC that includes additional, broader claims to the Company's exclusive Recursive Feature Elimination (RFE) using Support Vector Machines ("SVM") or SVM-RFE method, the first patent for which issued in 2006.
The European Patent Office issued a notice of its intent to grant a patent covering HDC's SVM-based computer-aided image analysis techniques.

: iStockAnalyst.com Symbols Feed

CombiMatrix: Array Of Sunshine In '09?

A New Emerging Diagnostics Index

YM BioSciences Announces Phase 2 Metastatic Colorectal Cancer Results for Nimotuzumab

Nine Stocks Strike Back

Health Discovery Corporation Announces Additional Issued Patents and Notices of Allowance to Its Intellectual Property Portfolio

Safeguard Scientifics Announces Sale of 2.4 Million Additional Clarient Shares Pursuant to Overallotment Option

Safeguard Scientifics Announces Second Quarter 2009 Financial Results

Clarient to Present at Canaccord Adams 29th Annual Global Growth Conference on Wednesday, August 12th

Clarient Reports Second Quarter Revenue Up 40 Percent ; New Molecular Tests and Increased Case Volume Continue to Drive Revenue Growth; First Net Income Reported; Revenue Guidance Increased

Clarient Reports Second Quarter Revenue Up 40 Percent

Clarient to Release 2009 Second Quarter Financial Results On Tuesday, August 4th

Emerging Growth Equities, Ltd. Initiates Coverage of Clarient, Inc. With a Buy Rating and $4.50 Price Target

Health Discovery Corporation Announces Publication of Peer Reviewed Scientific Paper Demonstrating the Clinical Validity of the Four-Gene Prostate Cancer Test Licensed to Abbott, Quest Diagnostics and Clarient

Clarient Set to Join Russell 3000 Index

Form 4 CLARIENT, INC For: Nov 05 Filed by: SAFEGUARD SCIENTIFICS INC (10K)

Form 4 Daly David For: Nov 03 (10K)

Form 4 Daly David For: Oct 05 (10K)

Form 4 CLARIENT, INC For: Sep 18 Filed by: SAFEGUARD SCIENTIFICS INC (10K)

Form 4 Daly David For: Sep 03 (10K)

Form 4 WALLER GREGORY D For: May 13 (10K)

Form 4 Smith Dennis M Jr For: May 13 (10K)

Form 4 CLARIENT, INC For: Jul 30 Filed by: SAFEGUARD SCIENTIFICS INC (10K)

Form 4 Daly David For: Jul 13 (10K)

Form 4 LAMONT ANN H For: May 14 (10K)